Background: [
Background
Tumor angiogenesis is essential for cancer survival [1] . Many novel therapeutics have been developed which aim to target this process by acting as either angiogenesis inhibitors (e.g. by blocking the action of vascular endothelial growth factor) or as vascular disrupting agents, which target the extracellular matrix [2, 3] . Despite the recent advances in therapeutics, there remains a paucity of effective biomarkers which can predict the response of tumors in vivo to these treatments. One area of promise is the development of imaging agents that target the αvβ3 and αvβ5 integrins -a set of transmembrane proteins essential for maintaining the relationship between the cell and the extracellular matrix and that have been found to be upregulated on tumor vascular neoendothelium [4, 5] .
[ 18 F]fluciclatide is an arginine-glycine-aspartic acid (RGD) peptide which binds the αvβ3 and αvβ5 integrins with high affinity [6] . We have previously studied the dosimetry and biodistribution of this compound labelled with F-18 in healthy volunteers with positron emission tomography (PET) [7] and the uptake profile of the tracer in patients with metastatic breast cancer [8] . The latter study showed significantly higher radiotracer uptake in lung metastases from breast cancer compared to normal lung tissue. [ 18 F]galacto-RGD is a similar promising agent for studying integrin-related angiogenesis developed by Wester's group [9] , and subsequently studied by Beer et al. who demonstrated that there is high uptake of this compound in a variety of cancers including melanoma [10] and that uptake correlates with expression of the αvβ3 integrin measured using immunohistochemistry [11] .
The purpose of this study was to understand the relationship between perfusion assessed by [
15 O]H 2 O and 18 F-fluciclatide kinetics in non-small cell lung cancer (NSCLC) and melanoma, where Phase 1 trials of humanized antibodies and peptides targeted to integrins have shown promise [12, 13] . These two tumor types have also been shown to have varying degrees of αvβ3 and αvβ5 expression on tumor cells relative to vascular endothelium with melanoma suggested to have expression on both tumor and vascular endothelium and NSCLC suggested to have expression predominantly on the vascular endothelium [4] . The underlying hypothesis for the study was that fluciclatide retention in tumors is initially dependent on perfursion, but at later timepoints, retention is independent of perfusion.
Methods
Patients were recruited from oncology clinics at the Imperial College NHS Healthcare trust and the Royal Marsden Hospital NHS Trust. The study was approved by the hospital Local Research Ethics Committee in accordance with the Helsinki Declaration revised guidelines (2008). The eligibility criteria were as follows: patients aged ≤80 years old with a histological proven NSCLC or melanoma, and one site of measureable disease of ≥2-cm diameter, with a treatment-free interval of 3 weeks (or 4 weeks for radiotherapy to the imaging site), life expectancy of at least 3 months, haemoglobin ≤10 g/dL, granulocyte count of ≥1.5 × 10 9 , platelet count of ≥100 × 10 9 , adequate hepatic function; exclusion criteria: pregnant or lactating patients, sexually active patients who are not employing adequate contraception. Additional details are provided in Table 1 .
Radiosynthesis of
18 F-fluciclactide and PET scanning procedure
The chemical synthesis of the precursor of fluciclatide has previously been described [6] , radiolabelling was performed at Hammersmith Imanet as previously described on an automated module (TRACERlab FX F-N ; GE Healthcare). The specific activity and radiochemical purity of the injectate, determined by high-performance liquid chromatography (HPLC), was 320 GBq/μmol and 99.7 %, respectively. All patients were scanned on a PET-CT (GE-Discovery RX) scanner after being positioned such that the field of view (FOV) included the tumor volume of interest. The axial FOV of the scanner was 15.7 cm and the transaxial FOV was 70 cm. A low-dose CT scan (20 mA and 120 kV) was used for attenuation correction prior to the PET scan. A target dose of 600 MBq [ ]fluciclatide parent fraction and input function was carried out as described in [7] . 
Data analysis
In Equation 1, C T (t) indicates the tumor TAC, C a (t) the measured radioactivity concentration in arterial blood, K 1 the regional blood flow (mL/cm 3 /min), k2 (1/min) the transfer rate from tissue to blood, V b (unitless) the blood volume fraction and ⊗ the convolution operator. K 1 , k 2 , and V b were estimated for each VOI by fitting C T (t) to Equation 1 using the standard weighted non-linear least squares (WNLLS). WNLLS minimizes the weighted residual sum of squares (WRSS)
with p, t i , and n indicating respectively the parameter vector [K 1 ;k 2 ;V b ], the mid-time of the ith frame, and the number of frames. In Equation 2 weights wi were set to
Tomasi G 2009, [14] with Δ i and λ indicating respectively the duration of the ith frame and the half-life of 15 O. The delay between C a (t) and C T (t) was modelled by shifting C T (t) of i seconds (i = 0,1, …, 30) and then retaining the value of the delay which gave rise to the smallest WRSS.
A two-tissue reversible compartment model was used to model [ 18 F]fluciclatide kinetics, consistent with our previous study [8] . The metabolite-corrected measured arterial concentration of [
18 F]fluciclatide was used as input function for estimating with WNNLS the parameters K 1 (mL/cm 3 /min), k 2 (1/min), k 3 (1/min), k 4 (1/min), V b (unitless) for each VOI. Weights were computed from Equation 3. The parameter k 3 /k 4 ratio -a measure of the binding potential -was then computed for each VOI; as we previously reported [8] , this parameter was the best of a number of parameters examined to differentiate between healthy and tumor VOIs. K 1 , k 2, and V b were also estimated at the voxel level for [ 15 Figure 1A ,B, respectively. The quality of the fits was good for both tracers. Examples are displayed in Figure 2A To investigate the relationship between perfusion and [ 18 F]fluciclatide retention, which was not feasible at the VOI level due to the low number of subjects completing both scans, we compared SUVwater with SUVfluci RETENTION or SUVfluci DELIVERY at the voxel level. As expected, SUVwater was well correlated with SUVfluci DELIVERY, the correlation being statistically significant for voxels within all four tumors (p value <10 −4 for all VOIs). The correlation between SUVwater and SUVfluci RETENTION, on the other hand, was not statistically significant (Spearman p value >0.15 for all tumors). This information is displayed in Figure 4 , which shows the relationship between SUVwater (x-axis) and SUVfluci DELIVERY (y-axis, Figure 4A ,C,E,G for patients 1, 2, 3, and 7, respectively) and between SUVwater and SUVfluci RETENTION (y-axis, Figure 4B 
Discussion
There is an increasing need for effective biomarkers which can reliably predict the response to novel therapeutics acting as angiogenesis inhibitors or as vascular disrupting F ]fluciclatide in our previous report proved to be appropriate also for this dataset, and the mean k 3 /k 4 ratio obtained in this study (5.39 ± 1.46) was in good agreement with the results obtained in lung metastases (k 3 /k 4 = 6.09 ± 3.04).
The main limit in this initial study is the small sample size, as only four out of seven patients successfully completed both scans, which hampered the quantification of the relationship between K 1 of [ 15 
Conclusion
In conclusion, these preliminary results support the view that [ 18 F]fluciclatide binding (retention) is not dependent on perfusion, highlighting the potential of this radiotracer in the study of receptors expressed on the neovasculature. The study supports the use of late imaging protocols (60 min post injection) for assessment of [ 18 F]fluciclatide uptake.
